Research
Predictive biomarker for liver cancer associated with survival outcomes, effectiveness of systemic therapy
The Brief
- Liver cancer was the sixth most common cancer and the third leading cause of cancer-related deaths worldwide in 2022.
- Hepatocellular carcinoma (HCC) is the most common histological subtype, accounting for approximately 90% of liver cancers.
- A predictive biomarker for liver cancer has been linked to survival outcomes and the effectiveness of systemic therapy.
Why it matters
A biomarker that predicts survival and response to systemic therapy could help researchers and clinicians stratify liver cancer patients and evaluate treatments. The source material provided does not include further detail on its validation.
Who’s affected
- oncology researchers
- clinicians treating liver cancer patients
- patients with hepatocellular carcinoma
- #liver cancer
- #biomarkers
- #hepatocellular carcinoma
- #systemic therapy
- #cancer survival
Liver cancer was the sixth most common cancer and the third leading cause of cancer-related deaths worldwide in 2022, with hepatocellular carcinoma (HCC) as the most common histological subtype, accounting for approximately 90% of liver cancers. Despite this, biomarkers that…